{"id":49129,"date":"2018-09-19T01:00:00","date_gmt":"2018-09-26T01:55:32","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/2018\/09\/26\/csco-%e4%bb%8a%e6%97%a5%e5%bc%80%e5%b9%95%ef%bc%8c%e4%b8%ad%e5%9b%bd%e5%8c%bb%e8%8d%af%e6%96%b0%e9%94%90%e5%b0%86%e5%b8%a6%e6%9d%a5%e5%93%aa%e4%ba%9b%e8%bf%9b%e5%b1%95%ef%bc%9f\/"},"modified":"2018-09-26T09:55:33","modified_gmt":"2018-09-26T01:55:33","slug":"csco-%e4%bb%8a%e6%97%a5%e5%bc%80%e5%b9%95%ef%bc%8c%e4%b8%ad%e5%9b%bd%e5%8c%bb%e8%8d%af%e6%96%b0%e9%94%90%e5%b0%86%e5%b8%a6%e6%9d%a5%e5%93%aa%e4%ba%9b%e8%bf%9b%e5%b1%95%ef%bc%9f","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/49129\/","title":{"rendered":"CSCO | \u4eca\u65e5\u5f00\u5e55\uff0c\u4e2d\u56fd\u533b\u836f\u65b0\u9510\u5c06\u5e26\u6765\u54ea\u4e9b\u8fdb\u5c55\uff1f"},"content":{"rendered":"
\n

\u258e\u836f\u660e<\/span><\/strong>\u5eb7\u5fb7\/\u62a5\u9053<\/span><\/strong><\/strong><\/strong><\/strong><\/span><\/strong><\/strong><\/p>\n


<\/span><\/p>\n

\u7f16\u8005\u6309\uff1a<\/span><\/strong>2018\u5e74CSCO\u5b66\u672f\u5e74\u4f1a\u5373\u5c06\u4e8e\u53a6\u95e8\u62c9\u5f00\u5e37\u5e55\u3002\u672c\u6b21\u4f1a\u8bae\u4e2d\uff0c\u591a\u5bb6\u4e2d\u56fd\u751f\u7269\u533b\u836f\u65b0\u9510\u4f01\u4e1a\u5c06\u5e26\u6765\u5176\u5728\u7814\u836f\u7269\u7684\u6700\u65b0\u8fdb\u5c55\u3002\u672c\u6587\u7531\u836f\u660e\u5eb7\u5fb7\u8fdb\u884c\u76d8\u70b9\uff0c\u4fe1\u606f\u4f9b\u884c\u4e1a\u5206\u4eab\u4e0e\u53c2\u8003\u3002<\/span><\/p>\n


<\/p>\n

\"CSCO<\/p>\n


<\/p>\n

\u57fa\u77f3\u836f\u4e1a\uff1aPD-L1\u5355\u6297\u5c06\u9996\u5ea6\u4eae\u76f8CSCO\u5e76\u7b2c\u4e00\u6b21\u6b63\u5f0f\u53e3\u5934\u62a5\u544a<\/strong><\/span><\/p>\n


<\/strong><\/span><\/p>\n

CS1001\u662f\u4e00\u6b3e\u9488\u5bf9PD-L1\u7684\u5355\u514b\u9686\u6297\u4f53\uff0c\u7531OMT\u8f6c\u57fa\u56e0\u52a8\u7269\u5e73\u53f0\u4ea7\u751f\uff0c\u8be5\u5e73\u53f0\u53ef\u5b9e\u73b0\u5168\u4eba\u6e90\u6297\u4f53\u7684\u4e00\u7ad9\u5f0f\u751f\u4ea7\u3002\u4f5c\u4e3a\u4e00\u79cd\u5168\u4eba\u6e90\u5168\u957f\u7684\u6297PD-L1\u5355\u514b\u9686\u6297\u4f53\uff0cCS1001\u4e0e\u4eba\u4f53\u81ea\u8eab\u5929\u7136G\u578b\u514d\u75ab\u7403\u86cb\u767d4\uff08IgG4\uff09\u5341\u5206\u76f8\u4f3c\uff0c\u53ef\u4ee5\u964d\u4f4e\u60a3\u8005\u7684\u514d\u75ab\u539f\u6027\u548c\u6bd2\u6027\u98ce\u9669\uff0c\u5728\u540c\u7c7b\u836f\u7269\u4e2d\u5177\u6709\u72ec\u7279\u4f18\u52bf\u3002<\/strong><\/span><\/p>\n


<\/p>\n

2017\u5e7410\u6708\u4ee5\u6765\uff0c\u57fa\u77f3\u836f\u4e1a\u5f00\u5c55\u4e86\u4eba\u4f531\u671f\u4e34\u5e8a\u7814\u7a76\uff08CS1001-101\uff09\uff0c\u4ee5\u8bc4\u4f30CS1001\u7528\u4e8e\u4e2d\u56fd\u665a\u671f\u80bf\u7624\u60a3\u8005\u7684\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u3001\u836f\u4ee3\u52a8\u529b\u5b66\u548c\u6297\u80bf\u7624\u6d3b\u6027\u30021a\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u5242\u91cf\u722c\u5761\uff09\u5df2\u4e8e2018\u5e745\u6708\u5b8c\u6210\uff0c1b\u671f\u4e34\u5e8a\u7814\u7a76\uff08\u5242\u91cf\u6269\u5c55\uff09\u5df2\u542f\u52a8\u60a3\u8005\u62db\u52df\u3002<\/span><\/p>\n


<\/p>\n

\u4e0e\u6b64\u540c\u65f6\uff0c\u5305\u62ec\u9488\u5bf9\u4e2d\u56fd\u9ad8\u53d1\u75c5\u7387\u3001\u60a3\u75c5\u7387\u80bf\u7624\u7684\u51e0\u9879\u5173\u952e\u6027\u4e34\u5e8a\u7814\u7a76\u6b63\u5728\u8fdb\u884c\u3002\u4eca\u5e746\u6708\uff0c\u4e24\u9879\u5173\u952e\u76842\u671f\u7814\u7a76\u5df2\u7ecf\u542f\u52a8\uff0c\u65e8\u5728\u63a2\u7d22CS1001\u5728\u81ea\u7136\u6740\u4f24\u7ec6\u80de\/ T\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CS1001-201\uff09\u548c\u7ecf\u5178\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08CS1001-202\uff09\u60a3\u8005\u4e2d\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002<\/span><\/p>\n


<\/p>\n

\n

\u9898\u76ee\uff1a<\/strong>Preliminary safety, pharmacokinetics and efficacy results from a Phase I study of CS1001, PD-L1 monoclonal antibody in patients with advanced tumors<\/span><\/p>\n

CS1001\uff0cPD-L1\u5355\u514b\u9686\u6297\u4f53\u5728\u665a\u671f\u80bf\u7624\u60a3\u8005\u4e2dI\u671f\u7814\u7a76\u7684\u5b89\u5168\u6027\uff0c\u836f\u4ee3\u52a8\u529b\u5b66\u548c\u6548\u679c\u7684\u521d\u6b65\u7ed3\u679c<\/span><\/p>\n

\u8bb2\u8005\uff1a<\/strong>\u9f9a\u7ee7\u82b3<\/span><\/p>\n

\u5355\u4f4d\uff1a<\/strong>\u5317\u4eac\u5927\u5b66\u80bf\u7624\u533b\u9662<\/span><\/p>\n

\u4e13\u573a\uff1a<\/strong>CSCO \u514d\u75ab\u6cbb\u7597\u4e13\u5bb6\u59d4\u5458\u4f1a-\u514d\u75ab\u6cbb\u7597\u4e13\u573a<\/span><\/p>\n

\u65f6\u95f4\uff1a<\/strong>2018\u5e749\u670821\u65e5\u4e0a\u534811:10-12:02<\/span><\/p>\n<\/blockquote>\n


<\/p>\n

\u518d\u9f0e\u533b\u836f\uff1aniraparib\u4e2d\u56fd\u60a3\u8005\u6570\u636e\u9996\u6b21\u516c\u5e03\uff0cbrivanib\u4e8c\u7ebf\u6cbb\u7597HCC\u521d\u6b65\u663e\u793a\u6297\u80bf\u7624\u6d3b\u6027<\/span><\/strong><\/span><\/p>\n


<\/span><\/strong><\/span><\/p>\n

N<\/span>iraparib\u662f\u4e00\u79cd\u9ad8\u6548\u3001\u6bcf\u65e5\u4e00\u6b21\u7684\u9009\u62e9\u6027\u53e3\u670dPARP\u6291\u5236\u5242\u3002Niraparib\u57282017\u5e743\u6708\u548c11\u6708\u5206\u522b\u5728\u7f8e\u56fd\u548c\u6b27\u76df\u83b7\u6279\u4f5c\u4e3a\u5bf9\u94c2\u7c7b\u5316\u7597\u6709\u5b8c\u5168\u6216\u90e8\u5206\u53cd\u5e94\u7684\u590d\u53d1\u4e0a\u76ae\u6027\u5375\u5de2\u764c\u3001\u8f93\u5375\u7ba1\u764c\u6216\u539f\u53d1\u6027\u8179\u819c\u764c\u60a3\u8005\u7684\u7ef4\u6301\u6cbb\u7597\u3002<\/span><\/p>\n


<\/p>\n

\u518d\u9f0e\u533b\u836f\u671f\u5f85niraparib\u6210\u4e3a\u4e2d\u56fd\u591a\u79cd\u5b9e\u4f53\u7624\u7c7b\u578b\u7684\u201cfirst-in-class\u201d\u836f\u7269\uff0c\u5e76\u4e14\u5df2\u7ecf\u542f\u52a8\u4e86\u591a\u9879\u8bd5\u9a8c\uff0c\u5305\u62ec\u5375\u5de2\u764c\u3001\u5c0f\u7ec6\u80de\u80ba\u764c\u7b49\u30022018 CSCO\u4e0a\uff0c\u5c06\u9996\u6b21\u516c\u5e03niraparib\u5728\u4e2d\u56fd\u5375\u5de2\u764c\u60a3\u8005\u4e2d\u7684\u6570\u636e\u3002<\/span><\/p>\n


<\/p>\n

\n

\u9898\u76ee\uff1a<\/span><\/strong>\u4e00\u9879\u8bc4\u4ef7niraparib \u5728\u4e2d\u56fd\u5375\u5de2\u764c\u60a3\u8005\u4e2d\u7684\u836f\u4ee3\u52a8\u529b\u5b66\u548c\u5b89\u5168\u6027\u7684I\u671f\u4e34\u5e8a\u7814\u7a76<\/span><\/p>\n

\u8bb2\u8005\uff1a<\/span><\/strong>\u9ad8\u96e8\u519c <\/span><\/p>\n

\u5355\u4f4d\uff1a<\/span><\/strong>\u5317\u4eac\u5927\u5b66\u80bf\u7624\u533b\u9662<\/span><\/p>\n

\u4e13\u573a\uff1a<\/span><\/strong>CSCO \u5987\u79d1\u80bf\u7624\u4e13\u5bb6\u59d4\u5458\u4f1a-\u5987\u79d1\u80bf\u7624\u2014\u5375\u5de2\u764c\u4e13\u573a<\/span><\/p>\n

\u65f6\u95f4\uff1a<\/span><\/strong>2018\u5e7409\u670821\u65e5\u4e0b\u5348 15:36-15:42<\/span><\/p>\n<\/blockquote>\n


<\/p>\n

Brivanib\u662f\u4e00\u79cd\u53e3\u670d\u3001\u5c0f\u5206\u5b50\u53cc\u9776\u5411TKI\u6291\u5236\u5242\u3002\u5728\u9488\u5bf9\u809d\u7ec6\u80de\u764c\uff08HCC\uff09\u7684\u56db\u98793\u671f\u8bd5\u9a8c\u4e2d\uff0c\u5747\u8868\u73b0\u51fa\u4e86\u6297\u80bf\u7624\u6d3b\u6027\u548c\u53ef\u63a7\u7684\u5b89\u5168\u6027\u3002<\/strong>\u57fa\u4e8e\u5bf9\u4e2d\u56fdHCC\u60a3\u8005\u75c5\u7406\u5b66\u548c\u5f53\u524d\u6cbb\u7597\u6807\u51c6\u7684\u7406\u89e3\uff0c\u5e76\u7ed3\u5408\u6b63\u5728\u8fdb\u884c\u7684\u76f8\u5173\u7814\u7a76\uff0c\u518d\u9f0e\u533b\u836f\u57282017\u5e74\u7b2c\u4e8c\u5b63\u5ea6\u542f\u52a8\u4e86brivanib\u4e8c\u7ebf\u6cbb\u7597\u4e2d\u56fd\u665a\u671fHCC\u60a3\u8005\u76842\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/span><\/p>\n


<\/p>\n

\n

\u9898\u76ee\uff1a<\/span><\/strong>\u63a2\u7d22\u4e0d\u540c\u5242\u91cf\u7684\u4e19\u6c28\u9178\u5e03\u7acb\u5c3c\u5e03\uff08ZL-2301\uff0cbrivanib\uff09\u5728\u7cfb\u7edf\u6027\u6cbb\u7597\u5931\u8d25\u6216\u4e0d\u8010\u53d7\u7684\u4e2d\u56fd\u665a\u671f\u809d\u7ec6\u80de\u764c\uff08HCC\uff09\u60a3\u8005\u4e2d\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u7684II\u671f\u7814\u7a76<\/span><\/p>\n

\u8bb2\u8005\uff1a<\/span><\/strong>\u79e6\u53d4\u9035<\/span><\/p>\n

\u5355\u4f4d\uff1a<\/span><\/strong>\u4e2d\u56fd\u4eba\u6c11\u89e3\u653e\u519b\u7b2c\u516b\u4e00\u533b\u9662<\/span><\/p>\n

\u4e13\u573a\uff1a<\/span><\/strong>CSCO \u809d\u764c\u4e13\u5bb6\u59d4\u5458\u4f1a-\u809d\u764c\u8bba\u575b 2<\/span><\/p>\n

\u65f6\u95f4\uff1a<\/span><\/strong>2018\u5e7409\u670822\u65e5\u4e0b\u5348 16:30-16:40<\/span><\/p>\n<\/blockquote>\n


<\/p>\n

\u767e\u6d4e\u795e\u5dde\uff1aTislelizumab\u548cZanubrutinib\u4eae\u76f8\u4e24\u5927\u4e13\u573a<\/span><\/strong><\/span><\/p>\n


<\/span><\/strong><\/span><\/p>\n

\u66ff\u96f7\u5229\u73e0\u5355\u6297\uff08<\/span>Tislelizumab<\/span>\uff09\u662f\u4e00\u79cd\u5728\u7814\u7684\u6297PD-1\u6297\u4f53\uff0c\u5df2\u7ecf\u663e\u793a\u51fa\u5bf9PD-1\u9ad8\u5ea6\u7684\u4eb2\u548c\u529b\u548c\u7279\u5f02\u6027\u3002\u901a\u8fc7\u751f\u7269\u5de5\u7a0b\u6280\u672f\uff0c\u66ff\u96f7\u5229\u73e0\u5355\u6297\u5728Fc\u533a\u57df\u533a\u522b\u4e8e\u76ee\u524d\u83b7\u6279\u7684PD-1\u6297\u4f53\uff0c\u4e34\u5e8a\u524d\u6570\u636e\u663e\u793a\uff0c\u8fd9\u4e00\u8bbe\u8ba1\u6216\u8bb8\u53ef\u4ee5\u6700\u5927\u9650\u5ea6\u51cf\u5c11\u4e0e\u5176\u4ed6\u514d\u75ab\u7ec6\u80de\u7684\u8d1f\u9762\u76f8\u4e92\u4f5c\u7528\u3002<\/span><\/p>\n


<\/p>\n

\u767e\u6d4e\u795e\u5dde\u5df2\u4e8e2018\u5e748\u670831\u65e5\u5411\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u9012\u4ea4\u66ff\u96f7\u5229\u73e0\u5355\u6297\u7684\u65b0\u836f\u7533\u8bf7\uff08NDA\uff09\uff0c\u7528\u4e8e\u6cbb\u7597\u590d\u53d1\/\u96be\u6cbb\u6027\u7ecf\u5178\u578b\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08R\/R cHL\uff09\u3002\u6b64\u5916\uff0c\u66ff\u96f7\u5229\u73e0\u5355\u6297\u7528\u4e8e\u5b9e\u4f53\u7624\u548c\u8840\u6db2\u80bf\u7624\u7684\u4e00\u7cfb\u5217\u7814\u7a76\u6b63\u5728\u8fdb\u884c\u4e2d\uff0c\u5305\u62ec\u9cde\u72b6\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u3001\u809d\u7ec6\u80de\u764c\u548c\u98df\u9053\u9cde\u72b6\u7ec6\u80de\u764c\u3001\u6dcb\u5df4\u7624\u3001\u5c3f\u8def\u4e0a\u76ae\u764c\u7b49\u3002<\/strong>\u6b64\u6b21CSCO\u4e0a\u4e5f\u5c06\u5e26\u6765\u9488\u5bf9\u4e2d\u56fd\u60a3\u8005\u7684\u591a\u9879\u7814\u7a76\u6570\u636e\u3002<\/span><\/p>\n


<\/p>\n

\n

\u9898\u76ee\uff1a<\/span><\/strong>Clinical Profile of Tislelizumab in Chinese Patients with Microsatellite Instability High (MSI-H) or Mismatch Repair-Deficient (MMRd) Solid Tumors: Preliminary Results from an Indication-Expansion Cohort<\/span><\/p>\n

\u66ff\u96f7\u5229\u73e0\u5355\u6297\u5728\u4e2d\u56fd\u5fae\u536b\u661f\u4e0d\u7a33\u5b9a\u6027\u9ad8\uff08MSI-H\uff09\u6216\u9519\u914d\u4fee\u590d\u7f3a\u9677\uff08MMRd\uff09\u5b9e\u4f53\u7624\u60a3\u8005\u4e2d\u7684\u4e34\u5e8a\u6982\u51b5\uff1a\u9002\u5e94\u75c7\u6269\u5c55\u7ec4\u7684\u521d\u6b65\u7ed3\u679c<\/span><\/p>\n

\u8bb2\u8005\uff1a<\/span><\/strong>\u6c88\u7433<\/span><\/p>\n

\u5355\u4f4d\uff1a<\/span><\/strong>\u5317\u4eac\u5927\u5b66\u80bf\u7624\u533b\u9662<\/span><\/p>\n

\u4e13\u573a\uff1a<\/span><\/strong>\u521b\u65b0\u836f\u7269\u4e34\u5e8a\u7814\u7a76\u6570\u636e\u4e13\u573a 1<\/span><\/p>\n

\u65f6\u95f4\uff1a<\/span><\/strong>2018\u5e7409\u670820\u65e5\u4e0b\u5348 16:45\u201316:55<\/span><\/p>\n<\/blockquote>\n


<\/p>\n

\n

\u9898\u76ee\uff1a<\/span><\/strong>Tislelizumab Combined with Chemotherapy as First-Line Treatment in Chinese Patients (Pts) with Advanced Lung Cancer<\/span><\/p>\n

\u66ff\u96f7\u5229\u73e0\u5355\u6297\u8054\u5408\u5316\u7597\u4f5c\u4e3a\u6cbb\u7597\u4e2d\u56fd\u665a\u671f\u80ba\u764c\u60a3\u8005\u7684\u4e00\u7ebf\u7597\u6cd5<\/span><\/p>\n

\u8bb2\u8005\uff1a<\/span><\/strong>\u738b\u6d01<\/span><\/p>\n

\u5355\u4f4d\uff1a<\/span><\/strong>\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662\u80bf\u7624\u533b\u9662<\/span><\/p>\n

\u4e13\u573a\uff1a<\/span><\/strong>CSCO \u5c0f\u7ec6\u80de\u80ba\u764c\/\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u4e13\u5bb6\u59d4\u5458\u4f1a-\u80ba\u764c\u514d\u75ab\u6cbb\u7597\u4e13\u573a<\/span><\/p>\n

\u65f6\u95f4\uff1a<\/span><\/strong>2018\u5e749\u670821\u65e5\u4e0a\u534811:30\u201311:38<\/span><\/span><\/p>\n<\/blockquote>\n


<\/p>\n

\n

\u9898\u76ee\uff1a<\/span><\/strong>Preliminary Results with Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)<\/span><\/p>\n

\u66ff\u96f7\u5229\u73e0\u5355\u6297\u6cbb\u7597\u4e2d\u56fd\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC\uff09\u60a3\u8005\u7684\u521d\u6b65\u7ed3\u679c<\/span><\/p>\n

\u8bb2\u8005\uff1a<\/span><\/strong>\u5468\u6e05<\/span><\/p>\n

\u5355\u4f4d\uff1a<\/span><\/strong>\u5e7f\u4e1c\u7701\u4eba\u6c11\u533b\u9662<\/span><\/p>\n

\u4e13\u573a\uff1a<\/span><\/strong>CSCO \u5c0f\u7ec6\u80de\u80ba\u764c\/\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u4e13\u5bb6\u59d4\u5458\u4f1a-\u80ba\u764c\u514d\u75ab\u6cbb\u7597\u4e13\u573a<\/span><\/span><\/p>\n

\u65f6\u95f4\uff1a<\/span><\/strong>2018\u5e749\u670821\u65e5\u4e0a\u534811:38\u201311:45<\/span><\/p>\n<\/blockquote>\n


<\/p>\n

Zanubrutinib\u662f\u4e00\u6b3e\u5728\u7814\u7684\u5f3a\u6548\u3001\u9ad8\u9009\u62e9\u6027\u7684\u5c0f\u5206\u5b50BTK\u6291\u5236\u5242\uff08Bruton\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff09\uff0c\u53ef\u963b\u65ad\u76f8\u5173\u4fe1\u53f7\u4f20\u9012\uff0c\u4ece\u800c\u6291\u5236\u6076\u6027\u589e\u6b96B\u7ec6\u80de\u7684\u751f\u957f\u5e76\u6740\u6b7b\u80bf\u7624\u7ec6\u80de\u3002Zanubrutinib\u4f5c\u4e3a\u4e00\u7c7b\u65b0\u836f\u6cbb\u7597\u590d\u53d1\/\u96be\u6cbb\u6027\u5957\u7ec6\u80de\u6dcb\u5df4\u7624\uff08MCL\uff09\u60a3\u8005\u7684\u4e0a\u5e02\u7533\u8bf7\u6b63\u7531\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u8fdb\u884c\u5ba1\u8bc4\u3002<\/strong>\u76ee\u524d\u6b63\u5728\u5c06\u5176\u4f5c\u4e3a\u5355\u836f\u548c\u8054\u5408\u7597\u6cd5\uff0c\u9488\u5bf9\u591a\u79cd\u6dcb\u5df4\u7624\u8fdb\u884c\u591a\u9879\u91cd\u8981\u7814\u53d1\u3002<\/span><\/p>\n


<\/p>\n

\n

\u9898\u76ee\uff1a<\/span><\/strong>A Phase 1 Clinical Study to Investigate the Safety, Tolerability and Pharmacokinetics\/Pharmacodynamics of BTK Inhibitor BGB-3111 in Chinese Patients with B-Cell Lymphoma<\/span><\/p>\n

Zanubrutinib\uff0c\u4e00\u4e2a\u9ad8\u9009\u62e9\u6027BTK\u6291\u5236\u5242\u5728\u4e2d\u56fd\u590d\u53d1\/\u96be\u6cbbB\u7ec6\u80de\u6dcb\u5df4\u7624\u60a3\u8005\u4e2d\u76841\u671f\u4e34\u5e8a\u7814\u7a76\u521d\u6b65\u62a5\u544a<\/span><\/p>\n

\u8bb2\u8005\uff1a<\/span><\/strong>\u6731\u519b<\/span><\/p>\n

\u5355\u4f4d\uff1a<\/span><\/strong>\u5317\u4eac\u5927\u5b66\u80bf\u7624\u533b\u9662<\/span><\/p>\n

\u4e13\u573a\uff1a<\/span><\/strong>\u521b\u65b0\u836f\u7269\u4e34\u5e8a\u7814\u7a76\u6570\u636e\u4e13\u573a 2<\/span><\/span><\/p>\n

\u65f6\u95f4\uff1a<\/span><\/strong>2018\u5e749\u670822\u65e5\u4e0a\u534808:30\u201308:45<\/span><\/p>\n<\/blockquote>\n


<\/p>\n

\u53c2\u8003\u8d44\u6599\uff1a<\/span><\/p>\n

[1] 2018\u5e74CSCO\u5e74\u4f1a\u65e5\u7a0b, Retrieved Sep 11, 2018, from http:\/\/reg.csco.org.cn\/reg2018\/dhrc.html
<\/span><\/p>\n

[2] CStone Pharmaceuticals Initiates Two Pivotal Phase II Studies of the Anti-PD-L1 Monoclonal Antibody CS1001. Retrieved Jun 13, 2018, from http:\/\/www.cstonepharma.com\/index.php?c=article&id=523<\/span><\/p>\n

[3] Zai Lab Doses First Patient in Phase III Trial of ZL-2306 (niraparib) in Patients with Small-Cell Lung Cancer in China. Retrieved Aug 28, 2018, from http:\/\/ir.zailaboratory.com\/phoenix.zhtml?c=254615&p=irol-newsArticle&ID=2365040<\/span><\/p>\n

[4] BeiGene Announces Acceptance of New Drug Application for Anti-PD-1 Antibody Tislelizumab in Hodgkin\u2019s Lymphoma in China. Retrieved Aug 31, 2018, from http:\/\/ir.beigene.com\/phoenix.zhtml?c=254246&p=irol-newsArticle&ID=2365642<\/span><\/p>\n


<\/span><\/p>\n

\u672c\u6587\u6765\u81ea\u836f\u660e\u5eb7\u5fb7\u5fae\u4fe1\u56e2\u961f\uff0c\u6b22\u8fce\u8f6c\u53d1\u5230\u670b\u53cb\u5708\uff0c\u8c22\u7edd\u8f6c\u8f7d\u5230\u5176\u4ed6\u5e73\u53f0\uff1b\u5982\u6709\u5f00\u8bbe\u767d\u540d\u5355\u9700\u6c42\uff0c\u8bf7\u5728\u6587\u7ae0\u5e95\u90e8\u7559\u8a00\uff1b\u5982\u6709\u5176\u4ed6\u5408\u4f5c\u9700\u6c42\uff0c\u8bf7\u8054\u7cfbwuxi_media@wuxiapptec.com<\/span>
<\/p>\n


<\/span><\/p>\n

\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

\u258e\u836f\u660e\u5eb7\u5fb7\/\u62a5\u9053 \u7f16\u8005\u6309\uff1a2018\u5e74CSCO\u5b66\u672f\u5e74\u4f1a\u5373\u5c06\u4e8e\u53a6\u95e8\u62c9\u5f00\u5e37\u5e55\u3002\u672c\u6b21\u4f1a\u8bae\u4e2d\uff0c\u591a\u5bb6\u4e2d\u56fd\u751f\u7269\u533b\u836f\u65b0\u9510\u4f01\u4e1a\u5c06 […]<\/p>\n","protected":false},"author":1,"featured_media":49130,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/49129"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=49129"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/49129\/revisions"}],"predecessor-version":[{"id":49132,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/49129\/revisions\/49132"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/49130"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=49129"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=49129"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=49129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}